GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 10 February, 2016
February 02 2016 - 10:07AM
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the
Company”), a biopharmaceutical company focused on discovering,
developing and commercializing novel therapeutics from its
proprietary cannabinoid product platform, will announce on 10
February, 2016 its first quarter financial results for the period
ending 31 December, 2015. GW will also host a conference call the
same day at 8:00 a.m. EST (1:00 p.m. GMT). Conference call
information will be provided in the financial results press
release. A replay of the call will also be available through the
Company's website (www.gwpharm.com) shortly after the call.
About GW Pharmaceuticals
plc
Founded in 1998, GW is a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform in a broad range of disease areas. GW commercialized the
world’s first plant-derived cannabinoid prescription drug,
Sativex®, which is approved for the treatment of spasticity due to
multiple sclerosis in 28 countries outside the United States. GW is
advancing an orphan drug program in the field of childhood epilepsy
with a focus on Epidiolex® (cannabidiol), which is in Phase 3
clinical development for the treatment of Dravet syndrome and
Lennox-Gastaut syndrome and which is also expected to enter Phase 3
clinical trials in the treatment of Tuberous Sclerosis Complex. GW
has a deep pipeline of additional cannabinoid product candidates
which includes Sativex in Phase 3 clinical development as a
potential treatment of pain associated with advanced cancer, as
well as compounds in Phase 1 and 2 trials for glioma, type 2
diabetes, and schizophrenia. For further information, please visit
www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
|
(Today) +44 20 3727 1000 |
Stephen
Schultz, VP Investor Relations (U.S.) |
|
|
917 280
2424 / 401 500 6570 |
|
|
|
|
FTI Consulting (Media Enquiries) |
|
|
|
Ben
Atwell / Simon Conway |
|
|
+ 44 20
3727 1000 |
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jul 2023 to Jul 2024